Xcout IntelAntiva Biosciences, Inc.
Antiva Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm focuses on biotechnology research and developing treatments for viral infections and precancerous conditions.
Subscribe to see Antiva Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Antiva Biosciences, Inc. at a glance
Antiva Biosciences, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $38.5M in April 2023. Xcout tracks 7 named people at Antiva Biosciences, Inc., including Kristine Ball (President & CEO, Antiva Biosciences).
Antiva Biosciences, Inc. leadership
- Kristine BallPresident & CEO, Antiva Biosciences
- Gail MaderisChairman
- Beni RovinskiManaging Director, Lumira Ventures
- Wende S. HuttonDirector
- Clifford M. SamuelPrincipal, PCMS1 Consulting
- David MoskowitzPrincipal, MPM Bioimpact
1 more named person on record for Antiva Biosciences, Inc., with roles, board committees and tenure — see the full roster →
Antiva Biosciences, Inc. funding rounds
The 6 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $38.5M | — | |
| Series E | $53M | 6 named | |
| SEC Form D filing | $15.6M | — | |
| Series C-1 | $15M | 8 named | |
| SEC Form D filing | $14.7M | — | |
| Series C | $22M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Antiva Biosciences, Inc. competitors
A few of Antiva Biosciences, Inc.'s closest competitors — see the full list of competitors and alternatives →
Centivax is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on accelerating the transition to a post-pathogen world by developing broad-spectrum vaccines, COVID-19 therapeutics, and antivenom antibodies.
Excision BioTherapeutics Inc. is a San Francisco-based clinical-stage biotechnology company focused on developing advanced gene editing therapeutics to treat infectious diseases.
Adynxx, Inc. is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, focused on biotechnology research and drug development.
Red Queen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on antiviral therapeutics, with its headquarters located in Cambridge, Massachusetts.
Antios Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Mendham, New Jersey, focused on developing innovative therapies to treat and cure chronic hepatitis B virus.
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Get Antiva Biosciences, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Antiva Biosciences, Inc. in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 8 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access